Reported Earnings • May 11
First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.70 in 1Q 2025) First quarter 2026 results: EPS: NT$1.00 (down from NT$1.70 in 1Q 2025). Revenue: NT$275.6m (down 13% from 1Q 2025). Net income: NT$71.7m (down 5.4% from 1Q 2025). Profit margin: 26% (up from 24% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • Mar 04
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (91% payout ratio). Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.13b market cap, or US$99.1m). Reported Earnings • Feb 28
Full year 2025 earnings released: EPS: NT$5.87 (vs NT$8.82 in FY 2024) Full year 2025 results: EPS: NT$5.87 (down from NT$8.82 in FY 2024). Revenue: NT$1.30b (up 3.4% from FY 2024). Net income: NT$261.6m (down 34% from FY 2024). Profit margin: 20% (down from 31% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Ankündigung • Feb 24
SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026 SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwan Reported Earnings • Nov 07
Third quarter 2025 earnings released: EPS: NT$1.73 (vs NT$2.60 in 3Q 2024) Third quarter 2025 results: EPS: NT$1.73 (down from NT$2.60 in 3Q 2024). Revenue: NT$336.7m (up 1.9% from 3Q 2024). Net income: NT$77.4m (down 33% from 3Q 2024). Profit margin: 23% (down from 35% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year. Reported Earnings • Aug 07
Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$2.21 in 2Q 2024) Second quarter 2025 results: EPS: NT$0.37 (down from NT$2.21 in 2Q 2024). Revenue: NT$324.8m (down 5.3% from 2Q 2024). Net income: NT$16.6m (down 83% from 2Q 2024). Profit margin: 5.1% (down from 29% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year. Upcoming Dividend • Jul 14
Upcoming dividend of NT$5.30 per share Eligible shareholders must have bought the stock before 21 July 2025. Payment date: 15 August 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.6%). Declared Dividend • Jun 11
Dividend increased to NT$5.30 Dividend of NT$5.30 is 51% higher than last year. Ex-date: 21st July 2025 Payment date: 15th August 2025 Dividend yield will be 6.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.9% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 09
First quarter 2025 earnings released: EPS: NT$1.70 (vs NT$1.96 in 1Q 2024) First quarter 2025 results: EPS: NT$1.70 (down from NT$1.96 in 1Q 2024). Revenue: NT$315.8m (up 17% from 1Q 2024). Net income: NT$75.8m (down 13% from 1Q 2024). Profit margin: 24% (down from 32% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year and the company’s share price has also increased by 12% per year. Ankündigung • Apr 30
SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2025 Results on May 07, 2025 SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2025 results on May 07, 2025 Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to NT$83.00, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 38% over the past three years. Reported Earnings • Mar 09
Full year 2024 earnings released: EPS: NT$8.82 (vs NT$5.63 in FY 2023) Full year 2024 results: EPS: NT$8.82 (up from NT$5.63 in FY 2023). Revenue: NT$1.26b (up 13% from FY 2023). Net income: NT$393.3m (up 57% from FY 2023). Profit margin: 31% (up from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 16% per year. Ankündigung • Feb 25
SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025 SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwan Ankündigung • Feb 15
SYN-TECH Chem. & Pharm. Co., Ltd. to Report Fiscal Year 2024 Results on Feb 24, 2025 SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report fiscal year 2024 results on Feb 24, 2025 New Risk • Nov 29
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Nov 18
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: NT$330.6m (flat on 3Q 2023). Net income: NT$116.0m (up 26% from 3Q 2023). Profit margin: 35% (up from 28% in 3Q 2023). Ankündigung • Oct 26
SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q3, 2024 Results on Nov 04, 2024 SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q3, 2024 results on Nov 04, 2024 Reported Earnings • Aug 13
Second quarter 2024 earnings released: EPS: NT$2.21 (vs NT$1.52 in 2Q 2023) Second quarter 2024 results: EPS: NT$2.21 (up from NT$1.52 in 2Q 2023). Revenue: NT$343.0m (up 40% from 2Q 2023). Net income: NT$98.6m (up 46% from 2Q 2023). Profit margin: 29% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year. Ankündigung • Jul 27
SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q2, 2024 Results on Aug 05, 2024 SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q2, 2024 results on Aug 05, 2024 Upcoming Dividend • Jul 12
Upcoming dividend of NT$3.50 per share Eligible shareholders must have bought the stock before 19 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 57% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.0%). Buy Or Sell Opportunity • Jul 08
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to NT$98.20. The fair value is estimated to be NT$79.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.4% over the last 3 years. Earnings per share has grown by 3.9%. Declared Dividend • Jun 22
Dividend increased to NT$3.50 Dividend of NT$3.50 is 17% higher than last year. Ex-date: 19th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (57% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 1.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: NT$1.96 (vs NT$1.47 in 1Q 2023) First quarter 2024 results: EPS: NT$1.96 (up from NT$1.47 in 1Q 2023). Revenue: NT$269.8m (flat on 1Q 2023). Net income: NT$87.4m (up 33% from 1Q 2023). Profit margin: 32% (up from 25% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 2% per year. Ankündigung • Apr 28
SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2024 Results on May 06, 2024 SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2024 results on May 06, 2024 Buy Or Sell Opportunity • Apr 23
Now 20% overvalued Over the last 90 days, the stock has fallen 2.5% to NT$82.30. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 2.5%. Buy Or Sell Opportunity • Mar 01
Now 20% overvalued Over the last 90 days, the stock has fallen 5.5% to NT$82.40. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 2.7%. Ankündigung • Feb 27
SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024 SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024. Location: No.168, Kai Yuan Rd., Hsin-Ying District Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider 2023 Audit Committee's Review Report; to consider 2023 Employees and Directors' Compensation Information; to consider Status of 2023 Cash Dividend Distribution; to consider 2023 Directors' Remuneration Information; to consider 2023 Business Report and Financial Statements; to consider distribution plan of 2023 earnings; and to consider other matters. Reported Earnings • Nov 08
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: EPS: NT$2.07 (down from NT$2.54 in 3Q 2022). Revenue: NT$330.4m (up 17% from 3Q 2022). Net income: NT$92.5m (down 18% from 3Q 2022). Profit margin: 28% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year. Reported Earnings • Aug 08
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: EPS: NT$1.51 (down from NT$3.11 in 2Q 2022). Revenue: NT$245.1m (down 17% from 2Q 2022). Net income: NT$67.5m (down 46% from 2Q 2022). Profit margin: 28% (down from 42% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) exceeded analyst estimates by 18%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year. Upcoming Dividend • Jul 14
Upcoming dividend of NT$3.00 per share at 3.5% yield Eligible shareholders must have bought the stock before 21 July 2023. Payment date: 18 August 2023. Payout ratio is a comfortable 44% but the company is not cash flow positive. Trailing yield: 3.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (1.7%). Reported Earnings • Mar 24
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: NT$6.62 (up from NT$3.38 in FY 2021). Revenue: NT$986.3m (up 32% from FY 2021). Net income: NT$295.3m (up 184% from FY 2021). Profit margin: 30% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) missed analyst estimates by 4.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Ankündigung • Dec 30
SYN-TECH Chem. & Pharm. Co., Ltd. Announces Appointment of Corporate Governance Officer SYN-TECH Chem. & Pharm. Co., Ltd. announced appointment of Corporate Governance Officer. Name, title, and resume of the previous position holder: N/A. Name, title, and resume of the new position holder: Maggie Juang /financial & accounting officer of Syn-Tech. Effective date: December 29, 2022. Price Target Changed • Nov 16
Price target decreased to NT$80.00 Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$76.40. Stock is up 9.1% over the past year. The company is forecast to post earnings per share of NT$3.02 for next year compared to NT$3.38 last year. Reported Earnings • Nov 06
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: NT$2.54 (up from NT$0.94 in 3Q 2021). Revenue: NT$281.8m (up 77% from 3Q 2021). Net income: NT$113.3m (up 302% from 3Q 2021). Profit margin: 40% (up from 18% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 37%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 07
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Second quarter 2022 results: EPS: NT$1.72 (up from NT$0.74 in 2Q 2021). Revenue: NT$209.1m (down 3.3% from 2Q 2021). Net income: NT$68.8m (up 209% from 2Q 2021). Profit margin: 33% (up from 10% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 192%. Over the next year, revenue is forecast to grow 32%, compared to a 39% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Ankündigung • Aug 03
SYN-TECH Chem. & Pharm. Co., Ltd. Announces Executive Changes SYN-TECH Chem. & Pharm. Co., Ltd. announced that Chun-Cheng, Hung/synthesis department manager of SCP, has replaced Chun-Tzer, Tsai/director of Syn-Tech, as Research and development officer. Syn-Tech has announced the change of research and development officer on July 1, 2022. The case was approved by the board of Syn-Tech on August 1, 2022. Upcoming Dividend • Jul 14
Upcoming dividend of NT$1.93 per share Eligible shareholders must have bought the stock before 21 July 2022. Payment date: 19 August 2022. Payout ratio is a comfortable 75% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (6.8%). In line with average of industry peers (2.8%). Ankündigung • Jul 03
SYN-TECH Chem. & Pharm. Co., Ltd. Announces Change of Research and Development Officer SYN-TECH Chem. & Pharm. Co., Ltd. announced change of research and development officer. Name, title, and resume of the previous position holder: Chun-Tzer, Tsai/director of Syn-Tech. Name, title, and resume of the new position holder: Chun-Cheng, Hung/synthesis department manager of SCP. Effective date is July 1, 2022. Ankündigung • Jun 22
SYN-TECH Chem. & Pharm. Co., Ltd. Announces Cash Dividend, Payable on August 19, 2022 SYN-TECH Chem. & Pharm. Co., Ltd. announced cash dividend of TWD 86,128,033 (TWD 2.15 per share). Ex-rights (Ex-dividend) date is July 21, 2022. Ex-rights (Ex-dividend) record date is July 27, 2022. Payment date of cash dividend distribution is August 19, 2022. Reported Earnings • May 10
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: NT$0.85 (down from NT$1.73 in 1Q 2021). Revenue: NT$159.5m (down 32% from 1Q 2021). Net income: NT$34.2m (down 34% from 1Q 2021). Profit margin: 22% (in line with 1Q 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 73%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Price Target Changed • Apr 27
Price target decreased to NT$66.00 Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$65.30. Stock is down 35% over the past year. The company is forecast to post earnings per share of NT$2.47 for next year compared to NT$3.38 last year. Reported Earnings • Mar 12
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: EPS: NT$3.38 (down from NT$6.21 in FY 2020). Revenue: NT$746.6m (down 24% from FY 2020). Net income: NT$103.8m (down 44% from FY 2020). Profit margin: 14% (down from 19% in FY 2020). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Over the next year, revenue is expected to shrink by 9.3% compared to a 20% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 5% per year. Reported Earnings • Nov 10
Third quarter 2021 earnings released: EPS NT$0.94 (vs NT$1.14 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: NT$159.2m (down 28% from 3Q 2020). Net income: NT$28.2m (down 18% from 3Q 2020). Profit margin: 18% (up from 16% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 09
Upcoming dividend of NT$4.00 per share Eligible shareholders must have bought the stock before 16 September 2021. Payment date: 07 October 2021. Trailing yield: 5.5%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.3%). Reported Earnings • Aug 06
Second quarter 2021 earnings released: EPS NT$0.74 (vs NT$2.35 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$216.3m (down 29% from 2Q 2020). Net income: NT$22.2m (down 69% from 2Q 2020). Profit margin: 10% (down from 23% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • May 06
First quarter 2021 earnings released: EPS NT$1.73 (vs NT$1.56 in 1Q 2020) The company reported a solid first quarter result with improved earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: NT$235.6m (flat on 1Q 2020). Net income: NT$52.0m (up 11% from 1Q 2020). Profit margin: 22% (up from 20% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment deteriorated over the past week After last week's 18% share price decline to NT$95.60, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 35% over the past three years. Ankündigung • Mar 18
SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million. SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million on March 16, 2021. The transaction will be settled by exchange of 4.5 million shares of SYN-TECH of NTD 75.24 per share. If there is insufficient exchange for one share, SYN-TECH shall, within 30 days after completing amendment registration, pay the difference between assessed business value and the share value in cash to SCP at once. The deal is subject to Standard Chemical obtaining approval from shareholders and is expected to close on October 1, 2021. Reported Earnings • Mar 18
Full year 2020 earnings released: EPS NT$6.21 (vs NT$5.31 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$983.8m (up 3.9% from FY 2019). Net income: NT$186.7m (up 17% from FY 2019). Profit margin: 19% (up from 17% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Ankündigung • Mar 17
SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021 SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021, at 14:00 Taipei Standard Time. Location: No.168, Kai Yuan Rd., Hsin-Ying District, Tainan City Taiwan Agenda: To consider 2020 Business Report; to consider Supervisors' Review Report on 2020 Financial Statements; to consider 2020 Employees' Compensation and Directors & Supervisors' Compensation Information; to consider Syn-Tech will transfer the API synthesis department that spinning-off from S.C.P, and issue new shares; to consider 2020 Business Report and Financial Statements; to consider the proposed distribution plan for year 2020 earnings; to consider the amendment to the Articles of Incorporation; to consider the amendment to the Procedures for Election of Directors and Supervisors; to consider the amendment to the Regulations Governing the Acquisition and Disposal of Assets; to consider the amendment to the Regulations Governing Loaning of Funds; and to consider other matters. Is New 90 Day High Low • Feb 27
New 90-day high: NT$82.50 The company is up 9.0% from its price of NT$75.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. Is New 90 Day High Low • Dec 21
New 90-day high: NT$77.30 The company is up 2.0% from its price of NT$75.50 on 23 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period. Reported Earnings • Nov 05
Third quarter 2020 earnings released: EPS NT$1.14 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$220.3m (down 20% from 3Q 2019). Net income: NT$34.3m (down 39% from 3Q 2019). Profit margin: 16% (down from 21% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 13
New 90-day low: NT$73.70 The company is down 16% from its price of NT$88.00 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period. Is New 90 Day High Low • Sep 22
New 90-day low: NT$75.60 The company is down 16% from its price of NT$89.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. 
